Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Neoplasm Metastasis 2Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Neoplasms 1Lymphoma, Non-Hodgkin 1Leukemia, Myeloid, Acute 1Carcinoma, Transitional Cell 1Breast Neoplasms 1

Interventions

pembrolizumab 26Gemcitabine 20Cisplatin 12Nivolumab 11Carboplatin 8Paclitaxel 7Docetaxel 7atezolizumab 6durvalumab 5Radiotherapy 5fludarabine 4enfortumab vedotin 4Ipilimumab 4Cyclophosphamide 4Vorinostat 3Magnetic Resonance Spectroscopy 3Fluorouracil 3Filgrastim 3Doxorubicin 3zimberelimab 2vocimagene amiretrorepvec 2tremelimumab 2romidepsin 2poly ICLC 2infigratinib 2erdafitinib 2cc-486 2belinostat 2avelumab 2amminedichloro(2-methylpyridine)platinum(II) 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Urinary Bladder Neoplasms × ALX148 × Clear all
NCT05524545 2025-07-25

A Study of Evorpacept (ALX148) With Enfortumab Vedotin for Subjects With Urothelial Carcinoma (ASPEN-07)

ALX Oncology Inc.

Phase 1 Completed
36 enrolled
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡